Worldwide Synthetic Biology Tools Market 2013-2023: Upstream Raw Materials Sources, Downstream Buyers and …Exclusive ReportageSynthetic Biology Tools Market report provides key statistics on the market status of the Synthetic Biology Tools Manufactur… Continue reading
Worldwide Synthetic Biology Tools Market 2013-2023: Upstream Raw Materials Sources, Downstream Buyers and …Exclusive ReportageSynthetic Biology Tools Market report provides key statistics on the market status of the Synthetic Biology Tools Manufactur… Continue reading
STAT |
A teen with Duchenne reports improvement on Solid’s gene therapy, and investors take notice
STAT 14-year-old boy with Duchenne muscular dystrophy 1 has regained some strength and function in his muscles following treatment with an experimental gene therapy from Solid Biosciences, the boy’s father tells STAT. And although it’s just a single case … |
News-Medical.net |
Flow of cerebrospinal fluid found to be key signal for neural stem cell renewal
News-Medical.net Stem cells in the brain can divide and mature into neurons participating in various brain functions, including memory. In a paper published in the journal ‘Cell Stem Cell‘, scientists at Helmholtz Zentrum München and Ludwig-Maximilians-Universität … Novel robotic system can grow mini human organsDeccan Herald Stem Cell Cure Offering Safe and Effective Stem Cell Treatments for Muscular DystrophyDigital Journal 2022 Animal Stem Cell Therapy Market: Global Manufacturers Analysis, Revenue, Market Share, Types, ApplicationsExpert Consulting Technical Progress –CryptoNexa all 41 news articles » |
Benzinga |
Uniqure Notches Bullish Initiation On Gene Therapy Prospects
Benzinga Uniqure’s dominant gene therapy platform with an AAVS vector; its potential “best-in-class” lead gene therapy candidate AMT-061 for treating hemophilia B; and pipeline optionality for treating Huntington’s and genetically driven heart disease create a … |
Benzinga |
Uniqure Notches Bullish Initiation On Gene Therapy Prospects
Benzinga Uniqure’s dominant gene therapy platform with an AAVS vector; its potential “best-in-class” lead gene therapy candidate AMT-061 for treating hemophilia B; and pipeline optionality for treating Huntington’s and genetically driven heart disease create a … |